Scorpius Holdings, Inc. operates in the contract biologics manufacturing niche but has lost its manufacturing assets due to foreclosure by secured noteholders. Despite a history of sporadic revenue gains, the company endures deepening operating and net losses coupled with severe liquidity constraints. Its delisting from NYSE American exacerbates operational risks in a highly regulated sector demanding CGMP compliance. Future prospects hinge on securing strategic transactions amid uncertain capital availability, while current financials reflect a steep negative return on equity and near-zero cash buffers.